Profil
Qimin Quan is the founder of Nanomosaic Inc. and held the titles of Director and Chief Scientific Officer.
Postes actifs de Qimin Quan
| Sociétés | Poste | Début |
|---|---|---|
Nanomosaic Inc.
 Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | Fondateur | - |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 1 |
|---|---|
Nanomosaic Inc.
Nanomosaic Inc. Miscellaneous Commercial ServicesCommercial Services Nanomosaic Inc. is a pioneering biotechnology company based in New York, NY. Nanomosaic Inc. develops innovative tools and technologies for biomarker detection and analysis. The company's flagship product, the Nanomosaic Tessie™ system, is a high-throughput platform for protein biomarker detection that allows researchers to analyze multiple samples simultaneously with high sensitivity and specificity. The system is designed to accelerate the discovery and development of biomarkers for various applications, including disease diagnosis, drug discovery, and precision medicine. Nanomosaic is the first commercial entity to leverage the power of nanoneedles for protein detection and quantification, enabling the development of assays for biomarker discovery and validation. With their proprietary technology, they offer rapid custom assay development and push the frontier of biomarker discovery and diagnostics. The company was founded by John J. Boyce, Qimin Quan, and Philippe Mourere has been the CEO since 2023. | Commercial Services |
